In short
Barbell Medicine Podcast Episode #390: Why Your Waist Matters More Than Your Weight — The Science of Visceral Fat
Episode Summary In this episode of the Barbell Medicine Podcast, Dr. Jordan Feigenbaum discusses the importance of waist measurement over weight when assessing health risks, especially in relation to visceral fat. He explains the various types of fat in the body, the mechanisms through which visceral fat contributes to metabolic diseases, and explores measurement techniques for tracking visceral fat at home. Furthermore, he addresses the impact of exercise, dietary interventions, and medications on fat loss and body composition.
---
Key Concepts and Discussions
- Understanding Body Weight and Measurement Issues
- The Scale Problem:
- Standard weight scales are not effective for tracking fat loss because they reflect total body mass, which includes muscle, water, and fat.
- Variability in weight can occur due to changes in water and glycogen storage.
- Body Recomposition:
- It is possible to lose fat and gain muscle simultaneously, leading to unchanged scale readings while waist circumference decreases.
- Importance of Waist Measurement:
- Waist circumference is a better predictor of metabolic health than body mass index (BMI).
- Normal-weight obesity can occur where individuals have a normal BMI but high levels of visceral fat.
- Visceral Fat and Its Dangers
- Definition and Distinction:
- Visceral fat is located in the abdominal cavity and is linked to numerous health risks.
- It is different from subcutaneous fat, which is less metabolically harmful and is found just beneath the skin.
- Mechanisms of Harm:
- Three main theories explain how visceral fat contributes to disease:
- Overspill Hypothesis: Visceral fat is a marker of excess fat storage, indicating that the body's safe storage capacity has been exceeded.
- Portal Vein Theory: Visceral fat drains directly to the liver, raising the risk of metabolic issues due to higher concentrations of free fatty acids.
- Hormonal Feedback Loop: Visceral fat affects testosterone levels in men, which can further exacerbate fat accumulation.
- Measuring Visceral Fat
- Measurement Techniques:
- MRI and CT scans are the gold standards for measuring visceral fat.
- Waist circumference can be a practical proxy, with different measurement sites yielding different results.
- Recommended sites include the iliac crest and the umbilicus (belly button).
- Waist-to-Height Ratio:
- A ratio below 0.5 is linked to lower mortality risk, making it a relevant metric.
- Impact of Lifestyle Interventions
- Exercise vs. Diet:
- Exercise, particularly aerobic activity, is more effective in reducing visceral fat than diet alone.
- Resistance training is crucial for preserving lean mass during weight loss.
- Sleep and Hormonal Environment:
- Adequate sleep (7-9 hours) regulates hunger hormones and supports metabolic health.
- Cortisol levels can influence fat distribution, particularly in visceral storage.
- Pharmacological Options
- GLP-1 Agonists:
- Medications like semaglutide and terzepatide aid in weight loss by reducing appetite.
- There can be concerns about lean mass loss with these medications, but exercise can mitigate this.
- Testosterone Therapy:
- TRT is beneficial for testosterone-deficient men but must be coupled with lifestyle changes for optimal results.
- The aromatase loop may complicate the relationship between visceral fat and testosterone levels.
---
Key Takeaways
- Relying solely on body weight can be misleading; waist circumference provides a more accurate assessment of health risks associated with visceral fat.
- Visceral fat poses significant health risks and tracking its levels through waist measurement is critical.
- Exercise, particularly aerobic training, is essential in targeting visceral fat effectively.
- Pharmacological interventions can be powerful tools but should be combined with lifestyle changes for the best outcomes.
---
Next Steps For listeners seeking evidence-based programs and consultations:
- Training Programs: [Barbell Medicine Training Programs](https://barbellmedicine.com/training-programs)
- Individualized Training Consultation: [Barbell Medicine Coaching](https://barbellmedicine.com/coaching)
- Resources on Health and Performance: [Barbell Medicine Resources](https://barbellmedicine.com/resources)
---
Additional Resources
- Links to relevant studies and articles:
- [PubMed Study 1](https://pubmed.ncbi.nlm.nih.gov/11502820/)
- [PubMed Study 2](https://pubmed.ncbi.nlm.nih.gov/33567185/)
- [PubMed Study 3](https://pubmed.ncbi.nlm.nih.gov/35658024/)
---
This episode emphasizes the importance of focusing on the quality of body composition rather than simply weight, advocating for a comprehensive understanding of health metrics and their implications for metabolic health.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Chapters
Tap a time to open that second in VOUnderstanding Scale Weight and Fat Distribution
0:45 to 3:26
Exploration of how scale weight misrepresents fat loss and body composition.
“The scale is measuring the wrong thing, but not because it's inaccurate.”
The Importance of Waist Measurement
3:26 to 7:52
Discussion on why measuring waist circumference is crucial for assessing health risks.
“Doctors sometimes call this normal weight obesity.”
The Science Behind Visceral Fat
7:52 to 14:00
Presentation of theories regarding the role and impact of visceral fat on health.
“Visceral fat overexpresses an enzyme called aromatase, which converts testosterone into estrogen.”
Genetic Adaptations and Fat Distribution
14:01 to 15:48
Explore how genetic adaptations influence fat storage patterns across populations.
“proposes that these differences in fat distribution reflect long-term genetic adaptations to the specific infectious disease pressures these different populations faced over thousands of generations.”
Understanding Waist Circumference Changes
15:49 to 18:08
Learn about the significance of waist circumference changes during weight loss.
“Okay, now let's talk about what the relationship between waist change and waist circumference change can actually tell you about the quality of the weight that you're losing.”
The Role of Sex in Weight Loss Metrics
18:09 to 20:46
Discover how weight loss ratios differ between men and women and their implications.
“The explanation here is fat distribution.”
Influence of Sleep and Cortisol on Weight Loss
20:47 to 21:27
Examine how sleep and cortisol levels affect weight loss efforts.
“A meta-analysis of 14 prospective cohorts, over 23 ,000 subjects, found essentially no meaningful relationship between psychosocial stress and subsequent weight gain.”
Mechanisms of Visceral Fat Reduction
22:30 to 24:26
Understand the biological mechanisms behind visceral fat reduction through exercise.
“In studies where aerobic exercise produces no meaningful weight loss, they have the same body weight start to finish, visceral fat still drops by about 6%.”
Exercise versus Diet in Fat Loss
24:27 to 27:25
Compare the effects of exercise and diet on visceral fat and lean mass.
“These are proteins secreted by contracting skeletal muscle that act as hormonal signals to other tissues.”
GLP-1s and Their Impact on Body Composition
27:26 to 28:00
Analyze the effects of GLP-1 drugs on weight loss and body composition.
“They create a calorie deficit primarily by reducing hunger, but they don't activate the adrenergic pathway.”
Show all 20 chapters
Exploring the Impact of GLP-1 Agonists on Body Composition
28:00 to 28:59
Learn how drugs like semaglutide and terzepatide affect body weight and fat loss.
“It's a reason to understand what needs to be added to get the most out of them.”
Understanding Lean Mass Loss and Muscle Preservation
29:00 to 31:14
Discover how lean mass loss is measured and the implications for muscle health.
“But before drawing conclusions from those numbers, we need to go through some context.”
The Misconceptions Around Muscle Loss and GLP-1 Agonists
31:15 to 34:05
Examine the framing of muscle loss risks associated with popular health media discussions.
“Now, the argument you'll hear from a lot of popular health media goes something like this.”
The Aromatase Regulation and Testosterone Dynamics
34:06 to 36:24
Understand how visceral fat affects testosterone levels through the aromatase loop.
“Appropriate use in the right patients with the right support isn't a controversial position.”
Testosterone's Role in Body Composition Across Ranges
36:25 to 39:34
Learn how testosterone levels influence lean mass and fat loss differently at various levels.
“Treating the testosterone without addressing the visceral fat leaves the underlying loop running.”
The Potential of Tessamorlin in Reducing Visceral Fat
39:35 to 41:30
Explore the limited but notable effects of Tessamorlin on visceral fat reduction.
“The cost side is also dose dependent and worth being clear about.”
Practical Guidelines for Measuring Waist Circumference
41:31 to 42:00
Get practical tips on how to measure waist circumference to monitor health.
“Its value instead is more like a proof of concept.”
Measuring Waist Circumference: Importance and Methodology
42:00 to 43:31
Learn how to accurately measure your waist circumference and its significance.
“The primary measurement is waist circumference.”
Exercise, Diet, and Pharmacological Support for Fat Loss
43:31 to 44:49
Discover the roles of exercise, diet, and medications in managing visceral fat.
“targeting visceral fat through mechanisms that calorie restriction doesn't touch.”
Understanding Changes in Body Composition Beyond the Scale
44:49 to 45:24
Understand how body composition changes can occur without visible weight loss.
“And if these lifestyle interventions plateau or if the clinical situation indicates we should move faster, pharmacological support can be useful, especially with GLP-1s.”
Transcript
Automatic transcript. May contain errors.0:00Dr. Jordan Feigenbaum:There's a finding in the exercise science literature that I think changes how most people should think about fat loss. In studies where subjects did aerobic exercise for months and didn't lose a single pound, the scale didn't move start to finish. Visceral fat still dropped by about 6%. The diet only grew. Same body weight, no weight loss. They showed about 1%. Same scale number, but roughly 6 times the effect on the fat that most directly predicts metabolic disease. But the scale didn't register any of it. That gap between what the scale reports and what's actually happening inside your body is what this episode is all about.
0:32Dr. Jordan Feigenbaum:We're going to cover the biology of fat distribution, why some fat is categorically more dangerous than other fat, how to actually measure the right things, and what the evidence says about the best ways to change them. Some of what we cover is going to push back on things that you've probably heard. I'm Dr. Jordan Feigenbaum. This is the Barbell Medicine Podcast.
0:58Dr. Jordan Feigenbaum:The scale is measuring the wrong thing, but not because it's inaccurate. A good scale is very accurate. The problem is what it's measuring. Scale weight combines every tissue compartment in your body into one single number. That's skeletal muscle, bone, organs, blood volume, the glycogen stored in your liver and muscle, whatever's in your GI tract right now, and several liters of water distributed across every cell in your body. Now, none of those compartments are static and all of them vary independently of fat tissue. Some of them vary considerably. Take glycogen storage. It alone varies by 300 to 500 grams based on what you've eaten in the past 48 hours.
1:33Dr. Jordan Feigenbaum:And each gram of glycogen holds roughly three to four grams of water alongside it in the cell. So that means that a carb heavy weekend, dinner out, a few drinks, birthday cake, they can all add two to four pounds to your scale reading and that has nothing to do with fat tissue. Even after a hard training session, the inflammatory response in stressed muscle draws in additional fluid. You can wake up a pound or two heavier after a workout you'd otherwise be proud of. Two to four pounds is the typical scale swing from a single carb heavy weekend through glycogen and water retention alone, but that's zero change in fat tissue.
2:05Dr. Jordan Feigenbaum:That's the floor of the noise that you're working with. There's a density issue too. Skeletal muscle has a density of about 1.06 grams per milliliter. Fat tissue sits at 0.9. That means that a pound of fat occupies roughly 15 to 20 % more physical space in your body than a pound of muscle. Yeah, one pound of fat is the same as one pound of muscle on a scale, fat just takes up more room. Now, if you've been training and replacing lower density fat with higher density muscle, your body is getting physically smaller while the scale stays flat or drifts only modestly. Clothes fit differently, your waist is getting smaller, the scale is unimpressed because mass is mass regardless of what it's made out of.
2:43Dr. Jordan Feigenbaum:This though is body recomposition, losing fat while preserving or gaining lean tissue simultaneously. It produces some of the best health outcomes available, but the scale is completely blind to it. If the scale hasn't moved, but your waist has, something is clearly working. The tape measure is just picking up something that the scale can't. Scale weight combines everything into one number, which makes it nearly useless for tracking fat specifically. What we actually want to track is where the fat is, and that requires a different tool and a short detour into some biology that may change how you think about your midsection.
3:14Dr. Jordan Feigenbaum:Not all fat is the same, and the type that lives inside your abdomen is operating on a completely different set of biological rules. You can have a completely normal BMI and be carrying dangerous amounts of the most metabolically disruptive fat in your body. Doctors sometimes call this normal weight obesity. That's when the person looks relatively lean, their height to weight ratio is normal, but internally they're carrying significant visceral fat that standard health screenings usually don't catch. It's because these screenings typically just use BMI and people often skip the waist circumference.
3:42Dr. Jordan Feigenbaum:I had a consultation with a gentleman not too long ago about weight management. He had a normal BMI, and on paper, he looked relatively healthy until I had to measure his waist, and it was at 40 inches. He also sent me his labs, and they told a different story too. He had impaired fasting glucose, his triglycerides were elevated, and he had low HDL. Every metabolic marker was pointing in the same direction, and this had probably been building for years, while everyone around him, including himself, was reassured by a normal BMI. Nobody had measured his waist. That scenario is more common than you think, and it's the reason why fat distribution matters more than fat amount in some cases.
4:17Dr. Jordan Feigenbaum:And when we say fat, subcutaneous fat is what most people think about. It sits between the skin and the muscle. You can grab it. You can find it on your hips, thighs, arms, and on top of your abdomen. Abdominal subcutaneous fat is relatively quiet, metabolically speaking. It produces fewer inflammatory signals per unit mass than visceral fat, and it doesn't drain directly into the liver. Peripheral subcutaneous fat at the hips and thighs appears to be actively protective in some respects. It efficiently traps circulating free fatty acids, and it produces hormones like adiponectin that seem to support metabolic health.
4:49Dr. Jordan Feigenbaum:Women store proportionally more fat here than men, which is part of why premenopausal women have a substantially lower cardiovascular risk profile than age-matched men at a similar BMI. Now, visceral fat is anatomically different. It sits inside the abdominal cavity, packed around the intestines, the liver, and the pancreas, You can't see it or feel it from the outside. Someone can look, lean standing in front of you, and be carrying substantial visceral fat internally. So what is visceral fat actually doing? The honest answer is that the scientific literature has three competing theories, and they're not equally supported by the evidence.
5:23Dr. Jordan Feigenbaum:Now, the first and most well-supported framework is what's called the overspill and ectopic fat hypothesis. The idea here is that visceral fat isn't necessarily a primary independent cause of metabolic disease. it's more accurately a marker that the body's safe subcutaneous storage capacity has been exceeded. Every person has what some researchers call a critical fat storage threshold. When subcutaneous capacity is saturated, fat overflows into the visceral compartment and, more importantly, into ectopic storage sites, primarily the liver. It's this ectopic fat accumulation, particularly liver fat or hepatic fat, that does the most direct metabolic damage.
6:01Dr. Jordan Feigenbaum:The data supporting this interpretation is pretty compelling. When researchers put visceral fat and fatty liver into the same statistical model and ask which one predicts metabolic syndrome independently, fatty liver wins decisively. In one analysis with an odds ratio exceeding 70, while visceral fat lost its independent significance entirely. When surgeons have selectively removed large amounts of visceral fat during bariatric procedures and compared outcomes to weight loss alone, there's no consistent additional metabolic benefit beyond what the weight loss itself produces. If visceral fat were an independent primary driver of disease, removing it surgically should provide a clear benefit above weight loss alone.
6:40Dr. Jordan Feigenbaum:The evidence, though, hasn't reliably shown that. The visceral depot appears to be a highly visible signal of a broader systemic problem rather than the main culprit itself. So that's the first theory. The second theory is the portal theory, and it's the one you hear most often. The fat depots inside the abdominal cavity drain through the portal vein, that goes to the liver, and every free fatty acid and inflammatory molecule released by the visceral fat goes straight into the liver circulation at concentrations the rest of the body never sees. The liver responds by producing more glucose, developing insulin resistance, and subsequently accumulating fat.
7:16Dr. Jordan Feigenbaum:And this cascade eventually is what produces metabolic syndrome. Portal vein concentrations of interleukin-6 are measurably higher, roughly 50%, when compared to systemic levels, which confirms that visceral fat is doing something that the portal theory predicts. But the theory's primacy is challenged by those same ometectomy trials. If the portal drainage route were the primary mechanism, severing it surgically should rapidly improve hepatic metabolism above and beyond what weight loss alone produces. Consistently, it hasn't. So the portal mechanism is real and contributing, but it's probably not the quote root cause.
7:50Dr. Jordan Feigenbaum:The third theory is hormonal and it operates through a feed-forward loop that's worth understanding in some detail. Visceral fat overexpresses an enzyme called aromatase, which converts testosterone into estrogen. In men, elevated estrogen signals the brain to reduce testosterone production. The brain is more sensitive to estrogen than testosterone in this regard. Lower testosterone levels then make visceral fat cells more efficient at accumulating or sequestering incoming fat from the bloodstream, which drives more aromatase activity, which drives testosterone lower. The loop runs in both directions and doesn't stop on its own.
8:26Dr. Jordan Feigenbaum:This mechanism is well validated, but it's better understood as a secondary loop that accelerates fat accumulation and complicates fat loss rather than the foundational driver of cardiovascular or metabolic disease. We'll come back to it in detail later because the clinical implications, particularly for men, are significant and usually under-discussed. On top of these three mechanisms, visceral fat also releases proteins called adipokines that function as hormones. For example, visceral fat increases the secretion of PAI1, plasminogen activator inhibitor 1, which impairs the body's ability to break down blood clots and creates a state of elevated clotting risk.
9:02Dr. Jordan Feigenbaum:It also increases angiotensinogen, which feeds directly into the renin-angiotensin - aldosterone system and contributes to hypertension, also known as high blood pressure. It also paradoxically underproduces adiponectin, the adipokine that normally increases insulin sensitivity, reduces hepatic glucose output, and protects blood vessels from plaque formation. More visceral fat means less adiponectin, which means less of the signal that protects you from the consequences of carrying visceral fat. That's a meaningful effect. I think that cardiorespiratory fitness is a confounder that's worth mentioning here because large prospective cohort data consistently shows that people with high fitness and high body fat have substantially lower cardiovascular mortality than people who are lean and unfit.
9:43Dr. Jordan Feigenbaum:Fitness partially decouples adiposity from mortality risk. This doesn't mean that visceral fat isn't a useful target. It clearly is. But the relationship between fat and health outcomes is not as clean as a simple linear story. Now, let's talk about how to actually measure visceral fat, because this is where a lot of the nuance lives and where most health communication falls short. MRI and CT are the gold standards for directly quantifying visceral fat volume. In clinical practice and for tracking at home, we use waist circumference as a proxy. It's a reasonably good one. Imaging studies show that waist circumference correlates with total abdominal fat above 0.8 in most data and with visceral fat specifically around 0.7.
10:22Dr. Jordan Feigenbaum:Those correlations are good enough for tracking change over time, which is what we actually care about. But here's where it gets more complicated than most people realize. There are three different standard measurement sites for waist circumference and they don't give you the same number. First up is NHANES. This is the large U.S. population surveillance study that provides many of the reference ranges used in American medicine. It measures at the iliac crest, the top of the hip bone. This is typically the lowest point of the trunk. The WHO standard measures at the midpoint between the bottom of the lowest rib and the top of the hip bone.
10:54Dr. Jordan Feigenbaum:The WHO standard measures at the midpoint between the bottom of the lowest rib and the top of the hip bone. And this is what was used to validate the widely cited clinical thresholds for waist circumference. 94 centimeters for men and 80 centimeters for women. Then there's the umbilicus, your belly button. It's the most practical site for self-tracking. One, it's the easiest landmark to hit consistently on your own. You can see it and feel it. And it shows the highest sensitivity to visceral fat changes over time when it comes to manually measuring your waist. It does typically read a few centimeters higher than the WHO midpoint site in people carrying central fat.
11:28Dr. Jordan Feigenbaum:Now, here's the practical implication. If you're measuring at the belly button and comparing it to the 94 and 80 centimeter clinical cutoffs for waist circumference, those are the ones that were validated at the WHO midpoint site, those thresholds are approximate guideposts for you, not necessarily hard lines. The trend matters more than where you land on any single reference anyway, so pick one site, measure it the same way every time, and track the direction. We recommend the belly button because it's just easier to locate. As far as how to measure, it should be first thing in the morning, after you go to the bathroom, but before you eat anything, you should be standing up straight and relaxed.
12:02Dr. Jordan Feigenbaum:Exhale gently and measure without bracing your trunk. Take three measurements and average them out. For the waist-to-height ratio, you can divide your waist circumference by your height as long as you're using the same units. A ratio below 0.5, so your waist is less than half of your height, is associated with substantially lower cardiovascular and all-cause mortality across virtually every population studied. The main thing here is you want to be below 0.5 but above 0.4 because that indicates that somebody might be carrying insufficient amounts of body fat. Still, waist-to-height ratio seems to outperform BMI as a single number predictor because it captures centrally located fat rather than just total mass.
12:41Dr. Jordan Feigenbaum:This is one of the reasons why we put it in the Barbell Medicine Vital 5. Now, there are ethnic-specific thresholds for waist circumference, and the biology behind why they exist matter more than what they're usually given credit for. For people of Asian descent, the clinical thresholds are lower, roughly 85 to 90 centimeters for men, 75 to 80 for women. For many South Asian populations, even tighter cutoffs have been proposed. And for individuals of West African descent, the standard thresholds may actually overestimate metabolic risk at a given waist measurement. These aren't necessarily arbitrary adjustments because they do reflect genuine differences in body composition and fat distribution that have specific biological origins.
13:20Dr. Jordan Feigenbaum:For any given BMI, individuals of South Asian descent carry higher mean body fat than people of European descent, with a greater proportion stored viscerally or in the abdomen. Individuals of West African descent tend to carry greater lean mass and lower total body fat at the same BMI. The relationship between an anthropometric measurement like BMI or waist circumference and actual internal fat distribution varies meaningfully by ancestry. The tool is reading something real, but what it's reading does vary by population. The evolutionary biology behind this is genuinely interesting, though I want to be clear up front that what follows is kind of a hypothesis, not necessarily settled science.
13:57Dr. Jordan Feigenbaum:One framework, called the Variable Disease Selection Hypothesis, proposes that these differences in fat distribution reflect long-term genetic adaptations to the specific infectious disease pressures these different populations faced over thousands of generations. It's an interesting argument, but the research is still developing and we should interpret it accordingly. But the argument goes something like this. Immune responses are metabolically expensive. Different pathogens impose different metabolic demands. Populations that are faced with intense pressure from specific types of infections may have evolved fat storage patterns that were optimized for fueling the immune responses those pathogens required.
14:34Dr. Jordan Feigenbaum:South Asian populations historically faced severe gastrointestinal infections, which monsoon conditions made endemic. The hypothesis is that visceral fat, positioned directly around the organs involved, draining to the liver, and capable of releasing energy and inflammatory signals into that local circulation, they may have been selectively favored as a fuel depot for mounting rapid local immune responses against gut-borne pathogens. The architecture that makes visceral fat metabolically problematic in a modern environment of calorie surplus may have been adaptive in an environment where gut infections were a leading cause of death.
15:08Dr. Jordan Feigenbaum:For populations with intensive historical exposure to malaria, a different pattern may have been favored. Malaria treatment requires sustained metabolically expensive fevers. Intramuscular adipose tissue, so that's fat stored directly within the muscle tissue, provides a local immediately accessible fuel source for the high metabolic demand of a fever. The hypothesis here is that populations facing heavy malarial burden may have evolved towards higher intramuscular fat storage for exactly that reason. Now again, these are hypotheses, not proven mechanisms, but they provide a biologically grounded framework for why identical waste measurements carry different metabolic implications across ancestries, one that goes deeper than an arbitrary clinical adjustment.
15:48Dr. Jordan Feigenbaum:The populations are genuinely different in ways that likely have deep historical roots. Okay, now let's talk about what the relationship between waist change and waist circumference change can actually tell you about the quality of the weight that you're losing. If you lost 10 pounds over the last two months, how much would your waist have changed? Most people couldn't answer that, and neither could their doctors, but that ratio is one of the most useful monitoring tools available, and it tells you something specific when it's off. Across studies tracking weight loss, the commonly cited figure is approximately 0.7 kilograms of weight loss per one centimeter of waist reduction, about 1.6 pounds per centimeter.
16:25Dr. Jordan Feigenbaum:Worth noting, the primary data behind this number comes from studies conducted in men. That matters for interpretation, and we'll come back to the sex differences shortly. For now, though, treat it as a rough orientation rather than a universal benchmark. In high-quality structured weight loss programs where the people are doing progressive resistance training, they're taking in adequate protein, and they're doing their conditioning, the ratio improves. Six-month intensive interventions have shown waist reductions of 10 to 14 centimeters alongside roughly 6 kilograms of weight loss, putting the ratio in the 0.4 to 0.6 kilograms per centimeter waist circumference reduction range.
16:59Dr. Jordan Feigenbaum:Less weight loss per centimeter of waist reduction because more of what's coming off is fat. At the other end, rapid weight loss without resistance training often pushes the ratio above 1 kg per cm waist circumference loss. That's the signal that lean tissue is being lost alongside fat. Lean tissue loss barely moves the tape measure. The scale cooperates, but the waistline doesn't. So the reference figure is roughly 0.7 kg per cm. Call it about 3 quarters of a kilogram per cm and remember this comes mainly from male study populations. Well-designed programs can get that ratio down towards 0.4 to 0.6, but if you're above 1.0 over 8 to 12 weeks, lean mass losses likely play a significant role.
17:41Dr. Jordan Feigenbaum:Again, these are population averages and individual variation is wide, driven by sex, baseline fat distribution, age, and the specifics of the weight loss program. Again, we can use them as calibration benchmarks, not as precise predictions. Back to the sex thing, women tend to show a less favorable ratio than men, particularly in the early phases of weight loss. Three kilograms of weight loss corresponds to about three and a half centimeters of waist reduction in men versus about 2.8 centimeters in women on average. The explanation here is fat distribution. Women store proportionally more fat in peripheral subcutaneous depots, the hips, the thighs, the gluteal region, and those depots tend to be mobilized before the abdominal depot responds significantly.
18:23Dr. Jordan Feigenbaum:The waist catches up, but typically later on in the weight loss journey. So what does this practically mean? We can track the weight and waist circumference under consistent conditions. First thing in the morning, after you go to the bathroom, but before you eat, daily weights averaged into a trend line are generally more informative than a single weekly number. The day-to-day swings from glycogen and fluid are noise, and the moving average filters them out. For waist circumference, weekly measurements at the same site are sufficient. You don't need to do it more than once a week. But over 8 to 12 weeks, if the weight is dropping, but the waist isn't moving proportionally, particularly if the ratio is running above of one kilo per centimeter of waist circumference reduction.
18:59Dr. Jordan Feigenbaum:If the waist is shrinking and the scale is flat, that's body recomposition, and you should enjoy it while it lasts. Ultimately, the scale tells you how much mass you've lost. The ratio tells you what that mass is made out of. And one of the less intuitive findings in the literature is that exercise doesn't just change the ratio by preserving lean mass, it targets visceral fat through a completely different biological mechanism that operates even when the scale doesn't move at all. But before we get into any interventions, there are two underappreciated factors that actively work against this whole program, and they don't get positioned that way often enough.
19:33Dr. Jordan Feigenbaum:The first is sleep. Sleep deprivation dysregulates two appetite-related hormones, leptin, which signals satiety, and ghrelin, which drives hunger. When you're constantly under-sleeping, your hunger signals are elevated and your fullness signals are blunted, independent of anything else in your program. Seven to nine hours of reasonably high-quality sleep is where the metabolic data lands. This isn't necessarily just a lifestyle recommendation, it's to help your physiology here, specifically around hunger and satiety. If you're chronically under sleeping, you're working against your own hormonal environment regardless of how well the rest of the program is designed.
20:07Dr. Jordan Feigenbaum:I wonder if that's what influencers mean when they say you have to balance your hormones. Speaking of hormones, the second thing here is cortisol. And I want to be specific here because the cortisol belly narrative has been both overstated and under discussed at the same time. The mechanisms are real. Visceral fat carries a higher density of glucocorticoid receptors than subcutaneous fat. Those are receptors for cortisol. Adipose tissue also contains an enzyme that locally regenerates active cortisol from its inactive form, which means that the visceral fat storage site is experiencing elevated cortisol activity even when a blood cortisol level looks normal.
20:40Dr. Jordan Feigenbaum:This is pretty well established. Now the population level effect is much smaller than the wellness industry is telling you. A meta-analysis of 14 prospective cohorts, over 23 ,000 subjects, found essentially no meaningful relationship between psychosocial stress and subsequent weight gain. About 69 % of the included studies found no significant relationship. The main driver of stress-related body composition changes is behavioral. Eating more, moving less, sleeping less, and not a direct hormonal rerouting of the fat into the visceral storage site, at least not by cortisol anyway. Addressing the behavior matters, and you should save your money on cortisol-blocking supplements because they're not really doing anything.
21:21Dr. Jordan Feigenbaum:Sleep and cortisol don't get the last word in the story, but they have earned a place early in the conversation about what's working against you. Craving the coffee flavor you love, but without the caffeine? Cachava's got you covered with their newest coffee flavor. This all-in-one nutrition shake delivers bold, authentic flavor crafted from premium decaffeinated Brazilian beans. Quality nutrition shouldn't be complicated. Just two scoops of cachava's all-in-one nutrition shake, and you've got 25 grams of protein, 6 grams of fiber, greens, and so much more. Whether you're craving that coffee taste to kickstart your morning ritual, or as a nutrient-packed reward to round out your afternoon, cachava keeps you fueled and satisfied wherever your day takes you.
22:03Plus, it actually tastes delicious. No fillers, no nonsense. Just the good stuff your body craves. And for the times you feel like switching it up, you've got seven flavors to choose from. all with the highest quality ingredients. Treat yourself to the flavor and nutrition your body craves. Go to cachava.com and use code fitness. New customers get 15 % off their first order. That's K-A-C-H-A-V-A.com code fitness.
22:28Dr. Jordan Feigenbaum:Now let's talk about the finding I opened the episode with, this time with the mechanism behind it. In studies where aerobic exercise produces no meaningful weight loss, they have the same body weight start to finish, visceral fat still drops by about 6%. Dietary restriction alone, without exercise and without weight loss, it's only about 1%. It's the same scale number, but roughly six times the visceral fat effect through a completely different pathway. This comparison is directional, not a controlled head-to-head analysis. The exercise and diet-only groups in that analysis aren't perfectly matched, but the finding is consistent across the literature and the mechanism explains why it has to be there.
23:06Dr. Jordan Feigenbaum:Visceral fat cells have some unique receptors that other cells don't. They carry a higher density of beta-3 adrenergic receptors, the receptors that respond to adrenaline and related catecholamines by activating fat release. They also carry a lower density of alpha-2 receptors, which normally serve as a break on fat mobilization. The net effect? Visceral fat responds far more readily to the catecholamine surge from vigorous exercise, especially aerobic exercise, when compared to subcutaneous fat. These receptor differences may have an evolutionary origin. Visceral fat appears to be built to function as a rapid release fuel reserve, one that drains directly to the liver through the portal vein during periods of intense physical demand or stress.
Read the full transcript
23:47Dr. Jordan Feigenbaum:The architecture that makes it metabolically problematic in a sedentary calorie surplus environment is the same architecture that makes it preferentially responsive to vigorous exercise. During a hard workout, especially if it's conditioning, the sympathetic nervous system produces a catecholamine spike. That's noradrenaline and adrenaline. These hit the visceral fat preferentially. This is one reason people who exercise consistently tend to carry lower visceral fat at the same body weight compared to people who don't work out, even when total calorie intake is similar. Repeated adrenergic activation from exercise is specifically mobilizing that internal fat storage site.
24:23Dr. Jordan Feigenbaum:The second mechanism is where things get really interesting because this is all about myokines. These are proteins secreted by contracting skeletal muscle that act as hormonal signals to other tissues. During vigorous exercise, working muscle releases interleukin-6 at levels 5 to 30 times above resting levels. This exercise-derived interleukin-6, or IL-6, enters the systemic circulation and acts on fat tissue to stimulate fat mobilization. The combination of visceral fat's receptor architecture and the circulating IL-6 signal means that visceral fat is being targeted through two independent pathways simultaneously during every hard training session.
25:00Dr. Jordan Feigenbaum:Your skeletal muscle, the tissue that is moving your body, is releasing a signaling molecule that tells fat cells to release stored energy. That's happening independently of the calorie deficit. Let's take a second with that. Your skeletal muscle, the tissue that moves your body, is releasing a hormone that tells fat cells to release stored energy. That's happening independently of what's going on with calories in and calories out. It's just a different biological pathway, and it's one that pure dietary restriction doesn't activate. Now, when it comes to exercise, aerobic training and HIIT high-intensity interval training generally outperform resistance training for acute visceral fat reduction.
25:38Dr. Jordan Feigenbaum:The catecholamine response and the calorie expenditure per unit of time from cardiovascular work are the primary drivers here. A meta-analysis found that exercise alone produces about 6 % visceral fat reduction versus 1 % from diet alone. That's the adrenergic and myokine mechanisms at work. Resistance training's contribution to visceral fat operates on a longer timeline. Lean tissue built or preserved through lifting weights protects resting metabolic rate, and prospective data consistently shows that lifting weights is more protective against age-related waist circumference gain over years than equivalent conditioning volume.
26:11Dr. Jordan Feigenbaum:The mechanism is metabolic, preserving the tissue that keeps your baseline energy expenditure elevated. Now when diet and exercise are combined, the waistline effect is larger than either produces alone. Head-to-head trials show diet alone produces waist reductions around 2.2 centimeters over a typical intervention period, 8 to 12 weeks. Now when we combine diet and exercise, then we see about a 5.7 centimeter reduction in waist circumference over the same time frame. Adding exercise also cuts lean mass loss roughly in half, from about 20 to 30 percent of weight loss as lean tissue on diet alone, down to approximately 10 to 15 % when exercise is included.
26:48Dr. Jordan Feigenbaum:As far as how much exercise is needed, the aerobic dose where visceral fat reduction reliably shows up in the data is around 150 minutes of moderate intensity work per week. There's still more to be had above that as more volume drives more effect because there's a dose-response relationship here. Now those mechanisms operate through the adrenergic and myokine pathways. They require physical contraction. You've got to exercise. This brings up a clinically important question about GLP-1s, which are the most effective weight loss pharmacology that we've ever seen. These drugs, semaglutide, terzepatide, and the emerging triple agonist, retatretide, they produce weight loss through appetite suppression and delayed gastric emptying mostly.
27:26Dr. Jordan Feigenbaum:They create a calorie deficit primarily by reducing hunger, but they don't activate the adrenergic pathway. Also don't produce the myokine signal. And the body's response to a sustained calorie deficit, regardless of how that deficit is created, is to draw on both fat and lean mass. This is exactly where the weight-to-waste ratio becomes clinically useful for people using these drugs. If the deficit is being created pharmacologically without exercise pathways being activated, the ratio tends to suffer. More lean mass in the mix, less waste per kilogram lost. This isn't a reason not to use these drugs necessarily, especially when they're clinically appropriate.
28:02Dr. Jordan Feigenbaum:It's a reason to understand what needs to be added to get the most out of them. Consider this. Semaglutide at full dose produces an average of about 15 % of initial body weight loss. Terzepatide, a dual GLP-1 and GIP agonist, reaches about 20%. Both show real reductions in visceral fat and liver fat that translate to improvements in metabolic syndrome. The direction is clearly right. But the body composition data is more complicated. DEXA sub-studies from the STEP1 trial. This is x-ray technology that looks at body composition and bone mineral density. in the step one trial is what looked at semaglutide over 68 weeks, well, approximately 39 % of the total weight loss was lean mass as measured by DEXA.
28:42Dr. Jordan Feigenbaum:Trisepatide does a little bit better. The SIRMALT1 trial showed that lean mass losses were about 24%. Rutatrutide, again, that's that triple agonist targeting GLP-1s, GIP, and now glucagon receptors, shows around 33 % lean mass in a recent study published in Lancet Diabetes and Endocrinology. But before drawing conclusions from those numbers, we need to go through some context. DEXA measures lean mass as everything that isn't fat or bone, including actual skeletal muscle, but also water, glycogen, organ tissue, and intramuscular fat. That's important. Fluid and glycogen shifts during rapid weight loss gets recorded as lean mass loss, as does intramuscular fat loss, which is a favorable adaptation.
29:24Dr. Jordan Feigenbaum:DEXA records them as lean mass loss too. These percentages from these studies likely overstate the actual skeletal muscle loss. We have some evidence to show that that's likely true. The Surpass 3 MRI sub-study tested this directly. It looked at fatty infiltration within the muscle, something we call myosteotosis, when people were using terzepatide. The drug significantly reduced intramuscular fat compared to placebo. That's a favorable adaptation, and it's exactly the kind of change DEXA would misattribute to lean mass loss. Functional data also points in the same direction. In the semilene study, patients on semaglutide showed a 4.5 kilo improvement in hand grip strength at 12 months.
30:01Dr. Jordan Feigenbaum:without exercise, mind you. And the prevalence of sarcopenic obesity dropped from 49 to 33%. A recent review concluded that skeletal muscle changes with GLP-1 treatments appear adaptive rather than pathological. That said, a 24 to 39 % lean mass loss on DEXA is comparable to what diet-only interventions produce without resistance training, which isn't really a high bar to clear. But what would happen if these drugs were combined with something that actually preserved muscle mass? and that's what the BELIEVE trial demonstrated directly. Bemagrumab, a myostatin pathway blocker combined with semaglutide, produced 22 % total weight loss with 93 % of it coming from fat mass versus 72 % coming from fat mass with semaglutide alone.
30:48Dr. Jordan Feigenbaum:The direction the field is moving is towards protecting lean mass while producing fat loss and the pharmacology to do that is beginning to exist. For people on GLP-1 agonists, adequate protein, which is around 1.6 grams of protein per kilogram body weight per day, and resistance training that is progressively loaded, make a meaningful difference to what's being lost and what's being preserved. The drug handles the deficit. What you do alongside of it shapes the composition of the outcome. Before we move on, I want to address something directly because the public conversation around GLP-1 agonists and muscle loss has a framing problem that I think is doing real harm to real patients.
31:24Dr. Jordan Feigenbaum:Now, the argument you'll hear from a lot of popular health media goes something like this. GLP-1 agonists cause lean mass loss. Therefore, they're dangerous. Therefore, people should be cautious about using them and otherwise skeptical. That argument treats the risks of the medication as if they exist in a vacuum, as if the alternative to taking the drug is something other than continuing to carry the weight. But here's what the lifestyle intervention data actually shows for people with obesity. Across intensive lifestyle programs, the best ones, with dietitians, behavioral support, structured exercise, consistent follow-up, roughly 1 in 10 people achieve and maintain clinically significant weight loss at 5 years.
32:02Dr. Jordan Feigenbaum:That's a success rate for people who engage with these programs. The other 9 are not dropping out or failing to try hard enough. It's just that the biology of weight regulation is genuinely difficult to override through effort alone, and suggesting otherwise is moralizing weight loss. These anti-obesity medications produce clinically significant weight loss in a substantially higher proportion of patients. Semaglutide at full dose averages around 15 % of starting body weight. Terzepatide does even better, closer to 20%. Again, these are average outcomes, not the best case scenarios. And when it comes to the muscle loss question, we just covered what the trial data actually shows.
32:37Dr. Jordan Feigenbaum:DEXA percentages that likely overstate real skeletal muscle loss because of fluid, glycogen, and intramuscular fat changes. Meaningful reductions in myosteotosis on terzepatide, hand grip strength improving on semaglutide, sarcopenic obesity prevalence dropping substantially in the semilene data. The concern is real, but the framing, that these drugs are consuming your muscle, it just doesn't hold up against the evidence when you look at it carefully. And there's also an intellectual consistency issue worth naming. The same people raising the loudest concerns about lean mass on GLP-1 agonists are largely not applying that same scrutiny to unregulated peptides, to aggressive calorie restriction without clinical supervision, or to vitamin D maxing, which is a documented cause of hypercalcemia and kidney damage when people take it in the quantities that some corners of the internet recommend.
33:24Dr. Jordan Feigenbaum:The selective application of alarm, specifically targeted at a drug class that is effective for obesity, is worth noticing. Untreated obesity at the clinical level carries a substantially elevated risk of cardiovascular disease, type 2 diabetes, sleep apnea, several types of cancer, osteoarthritis, fatty liver disease and all-cause mortality, to name a few. The conversation about whether a patient might lose some lean mass, lean mass that is substantially preserved with adequate protein intake and lifting weights, has to happen alongside the conversation about what happens to that patient if they don't lose the weight.
33:55Dr. Jordan Feigenbaum:Now, none of this means that GLP-1 agonists are appropriate for everyone, that we should put them in the water, or that the muscle loss data doesn't deserve attention in clinical practice. It certainly does, and we've walked through how to account for it. It means that the risk-benefit analysis has to include both sides of the coin. Appropriate use in the right patients with the right support isn't a controversial position. It's just medicine, and there are no gold stars for going throughout life without needing medicine. Now let's come back to the aromatase loop that I introduced earlier, because the clinical picture here is worth going through carefully.
34:25Dr. Jordan Feigenbaum:Visceral fat overexpresses aromatase, which converts testosterone to estradiol, a type of estrogen. In men, elevated estradiol feeds back to the hypothalamic-pituitary-gonadal axis, which is the brain-to-testes pathway for testosterone production. The hypothalamus reduces GnRH output. The pituitary follows with less luteinizing hormone, that's LH. With less LH reaching in the testes, they produce less testosterone. Viscereal fat is directly suppressing testosterone through this pathway. Testosterone deficiency then worsens the situation in a specific way. You see, testosterone normally inhibits the enzyme responsible for pulling triglycerides out of circulation and into the fat cell.
35:02Dr. Jordan Feigenbaum:When testosterone falls, that inhibition is lost. That means the visceral fat becomes more efficient at accumulating fat, which drives more aromatase activity, which suppresses testosterone further. The loop runs in both directions and it compounds over time. Now to be clear, aromatase is one of several ways that visceral fat reduces testosterone levels. Insulin resistance, which visceral fat promotes through the portal mechanism, directly impairs testosterone synthesis at the level of the testes. Elevated inflammatory cytokines from the adipose tissue, those are the adipokines, suppress the hypothalamic-pituitary-gonadal axis independently.
35:37Dr. Jordan Feigenbaum:And then there's detail for more recent research that often gets overlooked. When estradiol conversion was pharmacologically blocked in men with adequate testosterone levels, they gained body fat regardless of their testosterone dose. Estrogen, when it's produced naturally with testosterone present, appears to be critical for the body's ability to regulate fat accumulation. The clinical tendency to suppress estrogen in men on TRT, especially by TRT clinics, well, that can undermine exactly what you're trying to accomplish metabolically. See this pattern all the time. Gradual central weight gain over the years, declining energy, and decreased libido.
36:12Dr. Jordan Feigenbaum:The interpretation is usually testosterone deficiency, which may be true, but the cause is most commonly visceral fat accumulation, driving the hormonal changes. not a primary testosterone deficiency that's driving the fat game. Treating the testosterone without addressing the visceral fat leaves the underlying loop running. Testosterone's effect on body composition operates differently across three ranges, and which range you're in determines what's actually happening and what intervention makes sense. In testosterone-deficient men, those with confirmed low testosterone on laboratory analysis, and they have symptoms, testosterone, or specifically the lack thereof, is genuinely limiting to body composition.
36:51Dr. Jordan Feigenbaum:restoring it to normal physiological levels produces real changes. Lean mass begins increasing within the first month. One to three kilos over the next six months is represented in the literature. Visceral fat reduces over the same time frame as insulin sensitivity improves and the inhibitory effect on fat accumulation is restored. Now within the normal physiological range or eugenadal range, this is roughly 300 to 1 ,000 nanograms per deciliter depending on the lab. Testosterone is no longer the rate limiting factor for muscle gain. the training stimulus is. This is why men at the lower end of normal and men at the upper end of normal gain similar amounts of lean mass in response to the same resistance training program.
37:29Dr. Jordan Feigenbaum:The signal to the androgen receptors is sufficient across that range. What determines how much muscle mass is gained is the training load, not where the testosterone level sits. Now above the normal physiological level, this relationship changes. High doses of testosterone produce androgen concentrations well beyond what the body could ever generate on its own. At these levels, a clear dose-dependent relationship between testosterone exposure and lean mass emerges that simply isn't present within the normal range. The most well-described mechanism for rapid muscle growth and strength increases is forced cellular remodeling of muscle tissue.
38:04Dr. Jordan Feigenbaum:Superphysiological testosterone levels stimulate aggressive myonuclear addition from the satellite cell pool. These are basically stem cells for the muscles that can be called into action to help a muscle grow. To simplify, the more myonuclei someone has in their muscles, the more muscle protein can be produced, which means more potential muscle size. This overcomes the intrinsic biological constraint of the myonuclear domain, allowing muscle fibers to grow to sizes unattainable in the eugenatal state. This is also the structural basis for the two - to three-fold greater absolute gains in fat-free mass and strength observed when superphysiological testosterone is combined with exercise.
38:38Dr. Jordan Feigenbaum:High doses likely augment the non-hypertrophy-related strength gains, i.e. improved motor unit recruitment and contractility via non-genomic pathways, and significantly enhance recovery by reducing muscle protein breakdown. The most direct evidence for this is a controlled study that randomized men to four different groups for 10 weeks. Placebo with no exercise, placebo with resistance training, superphysiological testosterone levels with no exercise, and superphysiological testosterone with resistance training. The no-exercise testosterone group gained more lean mass than the exercise-only group.
39:11Dr. Jordan Feigenbaum:Testosterone plus exercise produced the most muscle gain. The anabolic signal at superphysiological concentrations is strong enough to drive muscle protein synthesis without a training stimulus. Exercise amplifies it substantially, but is no longer a requirement to produce the effect. Fat mass also decreases at these concentrations directly through androgen receptor-mediated inhibition of fat uptake by the cells and indirectly through the increased lean tissue, raising resting metabolic rate. The cost side is also dose dependent and worth being clear about. Regardless of whether someone is on replacement doses, that's testosterone replacement therapy or TRT, or if they're on super physiological doses of testosterone, endogenous production of testosterone shuts down.
39:52Dr. Jordan Feigenbaum:That's what your body normally makes on its own. The hypothalamic pituitary gonadal axis or HPG axis detects exogenous androgens from outside the body and stops generating it on its own. Recovery after stopping depends on the dose, the duration, and the specific compounds used and can be prolonged in some individuals. Based on the most recent evidence, TRT-level doses tend to produce neutral to beneficial changes in blood lipid levels and do not increase heart disease risk. At superphysiological doses, however, the lipid picture worsens, as does the risk of heart disease and a number of other conditions.
40:25Dr. Jordan Feigenbaum:How someone weighs the risks and benefits is a personal decision, but the takeaway is that the effect of testosterone on body composition varies wildly from testosterone deficient to normal to super physiological levels. There's one more pharmacological tool worth knowing about, mostly for what it reveals mechanistically. Tessamorlin is a synthetic growth hormone releasing hormone, that means it bumps up growth hormone, and it stimulates pulsatile physiological levels of growth hormone release from the pituitary. Now, this was used for HIV-associated lipodystrophy, mostly due to the medications that were being used to treat HIV at the time.
40:59Dr. Jordan Feigenbaum:And lipodystrophy just means, hey, people got storage of fat in weird areas, in this case, the visceral adipose tissue site, which was harmful. So in this population, it produced roughly a 15 % to 20 % reduction in the visceral fat area with essentially no change in subcutaneous fat. Now, to be clear, Tessa Moreland is FDA-approved only for HIV-associated lipodystrophy. The evidence in general obesity populations is limited, and its absolute effect on visceral fat is pretty small when you compare it to GLP-1s. It's really not competitive as a clinical tool for most patients in its current form.
41:32Dr. Jordan Feigenbaum:Its value instead is more like a proof of concept. The growth hormone axis can be selectively targeted to preferentially mobilize visceral fat without disturbing subcutaneous fat. And in fact, this is another one of the reasons why exercise works. When you exercise, growth hormone levels go up and that growth hormone binds to the growth hormone receptors in the visceral fat and that can reduce visceral fat storage. Now whether that mechanism at some point becomes clinically useful in the future, well, that is an open question. Here's where everything we've covered comes together in a practical framework.
42:01Dr. Jordan Feigenbaum:The primary measurement is waist circumference. Pick a site, the belly button being the most practical for self-monitoring, and measure it consistently. First thing in the morning, after you go to the bathroom, but before you eat, standing up straight, being relaxed. Exhale gently, don't brace or tense your midsection, and take three measurements. Average them together. You can do it once a week. That's totally sufficient. The two reference numbers to keep in mind are 94 centimeters for men, which is about 37 inches, and 80 centimeters for women. That's about 31 and a half inches. These are the WHO midpoint thresholds.
42:32Dr. Jordan Feigenbaum:So if you're measuring at the belly button, treat them as approximate. For people of South Asian descent, the thresholds are lower. And for individuals of West African descent, they may actually overestimate at a given measurement. For those people, we can use a waist-to-height ratio and below 0.5 is a good predictor of lower cardiovascular and all-cause mortality, again, provided it's above 0.4. It generally outperforms BMI across ethnicities because it captures central fat rather than just total mass. Again, that's why we made it a part of the Barbell Medicine Vital 5. For tracking the quality of the weight loss, the reference figure in general programs, again, derived primarily from studies in men, is about 0.7 kilograms of weight loss per centimeter of waist reduction.
43:11Dr. Jordan Feigenbaum:Well-structured weight loss programs are lower, 0.4 to 0.6. But if the ratio runs above 1 over 8 to 12 weeks, lean tissue loss is likely a significant contributor. The levers here are protein intake, make sure that's at least 1.6 grams of protein per kilogram body weight per day, and make sure you're lifting weights in a progressively loaded fashion. As far as exercise goes for visceral fat reduction, aerobic work is the primary driver through adrenergic and myokine pathways, targeting visceral fat through mechanisms that calorie restriction doesn't touch. Around 150 minutes of moderate intensity work per week is where the visceral fat reduction signal reliably appears in the data, but there's a dose-response relationship above that.
43:49Dr. Jordan Feigenbaum:Lifting weights doesn't produce the same short-term visceral fat loss, but it does protect lean mass loss during any calorie deficit. It also helps preserve resting metabolic rate long-term and appears to be more protective against age-related waist circumference gain than equivalent amounts of conditioning over the years. Both modalities have a role, and they're both doing different jobs. We should do both. Getting a sufficient amount of high-quality sleep is important to make sure that the hormonal environment around you supports what you're doing. Pharmacological options like GLP-1 agonists and TRT and appropriately diagnosed testosterone-deficient men, well, they work best when lifestyle inputs are in place, and they produce better compositional outcomes when people are eating enough protein and they're lifting weights.
44:28Dr. Jordan Feigenbaum:TRT and genuinely testosterone-deficient men addresses the aromatase loop from both directions simultaneously and seems to have a net beneficial effect when it comes to lipids. GLP-1 agonists are clinically powerful tools whose body composition outcomes are substantially better when there's an exercise foundation in place. For most people, exercise and diet are the foundation. Getting enough sleep makes everything work better. And if these lifestyle interventions plateau or if the clinical situation indicates we should move faster, pharmacological support can be useful, especially with GLP-1s.
44:58Dr. Jordan Feigenbaum:If we go back to the person from the introduction of this podcast, they did months of exercise, but the scale was flat the entire time. They still lost 6 % of their visceral fat. Nobody told them this was happening. The scale certainly didn't. But the tale of the tape measure and the ratio are the instruments that track what actually matters here. And it's worth knowing how to use them. And now you do. I'm Dr. Jordan Feigenbaum. Thanks for listening to the Barbell Medicine Podcast. Catch you next week and every week right here on the Barbell Medicine Podcast.
From the publisher
You can have a completely normal BMI and be on your way to cardiovascular disease, type 2 diabetes, and metabolic syndrome without triggering a single alert on a standard health screening. The fat that predicts metabolic risk most accurately isn't the fat your scale or your doctor is tracking. Dr. Jordan Feigenbaum breaks down the science of visceral fat — what it is, how it causes disease, how to measure it correctly at home for free, and what the evidence actually shows about exercise, GLP-1 medications, and testosterone.
- 00:00:00 Cold Open: The Visceral Fat Finding
- 00:00:49 The Scale Problem — What Body Weight Actually Measures
- 00:03:50 What Is Visceral Fat — and Why It's Not Just "Belly Fat"
- 00:05:04 Three Competing Theories: How Visceral Fat Actually Causes Disease
- 00:08:35 Adipokines: PAI-1, Angiotensinogen, and What Happens When Adiponectin Drops
- 00:09:52 How to Measure: Three Sites That Don't Give the Same Number
- 00:14:30 Clinical Thresholds, Ethnic Adjustments, and the Waist-to-Height Ratio
- 00:15:45 The Weight-to-Waist Ratio: Tracking the Quality of Your Fat Loss
- 00:19:20 Sleep, Cortisol, and Why the Hormonal Environment Has to Support the Work
- 00:21:24 Why Exercise Reduces Visceral Fat 6× More Than Diet Alone
- 00:22:02 Mechanism 1 — Beta-3 Adrenergic Receptors and Preferential Visceral Fat Mobilization
- 00:24:10 Mechanism 2 — Myokines: The Fat-Burning Signal Only Contracting Muscle Can Send
- 00:26:21 GLP-1 Agonists and Body Composition: What the Clinical Trials Actually Show
- 00:28:05 DXA's Blind Spot: Myosteatosis, Glycogen, and Why Lean Mass Numbers Are Inflated
- 00:30:10 SEMALEAN, the BELIEVE Trial, and the 1-in-10 Reality of Long-Term Lifestyle Programs
- 00:33:15 Testosterone, Visceral Fat, and the Aromatase Feed-Forward Loop
- 00:36:05 Three Testosterone Ranges: Deficient, Eugonadal, and Supraphysiological
- 00:38:05 The Bhasin 4-Group Study — and Why AAS Are a Class, Not a Synonym for TRT
- 00:39:33 Tesamorelin: The GHRH Analogue That Selectively Targets Visceral Fat
- 00:40:53 Practical Framework: What to Measure, When, and What to Do
- 00:43:20 Key Takeaways
- For evidence-based resistance training programs: barbellmedicine.com/training-programs
- For individualized training consultation: barbellmedicine.com/coaching
- Explore our full library of articles on health and performance: barbellmedicine.com/resources
- To join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/
- To consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.com
- Barbell Medicine Vital 5 Action Plan: https://www.barbellmedicine.com/vital-5-action-plan/
- https://pubmed.ncbi.nlm.nih.gov/11502820/
- https://pubmed.ncbi.nlm.nih.gov/33567185/
- https://pubmed.ncbi.nlm.nih.gov/35658024/
- https://pubmed.ncbi.nlm.nih.gov/40318682/
- https://pubmed.ncbi.nlm.nih.gov/41068996/
- https://pubmed.ncbi.nlm.nih.gov/41772149/
- https://pubmed.ncbi.nlm.nih.gov/23944298/
- https://pubmed.ncbi.nlm.nih.gov/20948519/
- https://pubmed.ncbi.nlm.nih.gov/27213481/
- https://pubmed.ncbi.nlm.nih.gov/23303913/
Our Sponsors:
* Check out Factor: https://factormeals.com/bbm50off
* Check out Quince: https://quince.com/BBM
Support this podcast at — https://redcircle.com/barbell-medicine-podcast/donations
Advertising Inquiries: https://redcircle.com/brands
Privacy & Opt-Out: https://redcircle.com/privacy
